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Sensitivity and Increases Adiponectin Concentrations
in Monkeys
Michael M. Swarbrick, Peter J. Havel, Arthur A. Levin, Andrew A. Bremer,
Kimber L. Stanhope, Madeline Butler, Sheri L. Booten, James L. Graham,
Robert A. McKay, Susan F. Murray, Lynnetta M. Watts, Brett P. Monia,
and Sanjay Bhanot
Department of Molecular Biosciences (M.M.S., P.J.H., K.L.S., J.L.G.), School of Veterinary Medicine, Department of
Nutrition (M.M.S., P.J.H., K.L.S., J.L.G.), and Department of Pediatrics (A.A.B.), School of Medicine, University of
California, Davis, Davis, California 95616; and Isis Pharmaceuticals Inc. (A.A.L., M.B., S.L.B., R.A.M., S.F.M., L.M.W.,
B.P.M., S.B.), Carlsbad, California 92008
Protein tyrosine phosphatase (PTP)-1B antagonizes insulin signaling and is a potential therapeutic
target for insulin resistance associatedwith obesity and type 2 diabetes. To date, studies of PTP-1B
have been limited by the availability of specific antagonists; however, treatment of rodents with
antisense oligonucleotides (ASOs) directed against PTP-1B improves insulin sensitivity, inhibits
lipogenic gene expression, and reduces triglyceride accumulation in liver and adipose tissue. Here
we investigated ASO-mediated PTP-1B inhibition in primates. First, PTP-1B ASO (ISIS 113715) dose-
dependently inhibited PTP-1B mRNA and protein expression in cultured monkey hepatocytes.
Subcutaneous administration of ISIS 113715 reduced PTP-1BmRNA expression in liver and adipose
tissue of normal-weightmonkeys by 40–50% and improved insulin sensitivity during an iv glucose
tolerance test (IVGTT). In obese, insulin-resistant rhesus monkeys, treatment with 20 mg/kg ISIS
113715 for 4 wk reduced fasting concentrations of insulin and glucose and reduced insulin re-
sponsesduringan IVGTT. In theseanimals, adiponectin concentrationswerealso increasedby70%,
most of which was an increase of high-molecular-weight oligomers. These effects were not ob-
served in monkeys on a lower, dose-escalation regimen (1–10 mg/kg over 9 wk). Overall, the
increase of adiponectin concentrations during ISIS 113715 treatment was correlated with the
lowering of insulin responses during IVGTT (r  0.47, P  0.042). These results indicate that
inhibition of PTP-1Bwith ASOs such as ISIS 113715may be a viable approach for the treatment and
prevention of obesity-associated insulin resistance and type 2 diabetes because they potently
increase adiponectin concentrations in addition to improving insulin sensitivity. (Endocrinology
150: 1670–1679, 2009)
Protein tyrosine phosphatases (PTPs) reduce the activationstate of the insulin receptor kinase and thereby inhibit pos-
treceptor signaling in insulin-responsive tissues such as liver,
muscle, and adipose (1). PTP activity in skeletal muscle and ad-
ipose tissue is increased in obesity and insulin resistance and is
reduced after weight loss (2, 3). Of the PTPs, PTP-1B has gen-
erated a great deal of interest as a potential therapeutic target for
insulin resistance and obesity, as in contrast to their wild-type
littermates, PTP-1B-null mice are resistant to these conditions
when placed on a high-fat diet (4). The lean phenotype in PTP-
1B-deficient mice is due to increased basal metabolic rate and
energy expenditure (5) as well as increased sensitivity to the ef-
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fects of exogenous leptin to reduce food intake and body weight
(6). In vitro, overexpressionof PTP-1B in cultured cells decreases
insulin-stimulated tyrosyl phosphorylation of insulin receptor
and insulin receptor substrate-1 (7), whereas application of neu-
tralizing antibodies directed against PTP-1B produces the oppo-
site effects (8).
Despite these advances, however, progress toward develop-
ing antagonists of PTP-1B as therapeutics for obesity and type 2
diabetes has been hampered by several factors, including selec-
tivity and bioavailability (9). Interestingly, an antisense oligo-
nucleotide (ASO) directed against PTP-1B has been shown to
reduce PTP-1BmRNAexpression in liver and adipose tissue (but
not skeletal muscle) by about 50% and to produce significant
glucose-lowering effects in hyperglycemic, insulin-resistant
ob/obanddb/dbmice (10). PTP-1BASOtreatmentofob/obmice
alsodown-regulated genes involved in lipogenesis in the liver and
adipose tissue and reduced adipose tissue triglyceride content
(11, 12). These latter effects are likely due to reductions in the
expression of sterol response element binding protein-1 (SREBP-
1c), an insulin-induced lipogenic transcription factor expressed
in liver and adipose tissue (13).
The objective of the present studywas to extend our previous
findings in rodents by investigating the effects of PTP-1B ASO
(ISIS 113715) administration in nonhuman primates. We first
established the specificity of ISIS 113715 for themonkey PTP-1B
gene in vitro. Next, we tested the ability of ISIS 113715 to inhibit
PTP-1B gene expression in insulin-sensitive tissues of normal-
weight cynomolgus monkeys. Subsequently we treated two
groups of obese, insulin-resistant rhesus monkeys with ISIS
113715 and examined its effects on fasting insulin and glucose
concentrations as well as insulin sensitivity as assessed by iv
glucose tolerance tests (IVGTTs).
Because PTP-1B deficiency in adipose tissue, resulting from
either genetic ablation or ASO treatment, has been reported to
interfere with insulin signaling (14) and to regulate the expres-
sionofgenes involved in lipogenesis (12),wealso investigated the
effects of ISIS 113715 treatment on plasma adiponectin concen-
trations. Adiponectin is an insulin-sensitizing adipocyte-derived
hormone that links adipocyte hypertrophy with insulin resis-
tance, inflammation, and atherosclerosis (15). Plasma adiponec-
tin concentrations are decreased in patients with metabolic and
cardiovascular diseases, including obesity and type 2 diabetes
(16). Adiponectin concentrations increase after weight loss (17)
and treatment with thiazolidinediones (18), drugs that improve
insulin sensitivity in adipose tissue (19).
Materials and Methods
Identification and characterization of ISIS 113715 as a
potent antisense inhibitor of PTP-1B expression in
monkeys
ISIS 113715has been identified as themost potent antisense inhibitor
ofmouse, rat, and humanPTP-1BmRNAs (10). ISIS 113715 is a 20-base
chimeric ASO inwhich a ribonucleaseH-sensitive stretch of 10 2-deoxy
residues is flanked on both sides with a stretch of five 2-O-(2-methoxy-
ethyl-ethyl) modifications, which increase binding affinity toward
mRNA sequences and confer nuclease resistance (20). Conservation of
the ISIS 113715 binding site in monkeys, located between nucleotides
862 and 882 of the coding sequence for PTP-1B in humans, was con-
firmed by PCR (data not shown).
Characterization of ISIS 113715 in monkey hepatocytes
in vitro
Primary cynomolgus monkey hepatocytes were obtained from Cell-
zDirect (Tucson, AZ) and plated onto collagen-coated plates using Wil-
liam’sEmedia containing10%fetal bovine serum(Invitrogen,Carlsbad,
CA). Cells were allowed to attach for 2 h and were then washed and
incubated overnight. ASOs were prepared by diluting in serum-freeWil-
liam’s E media containing Lipofectin (Invitrogen) at 3 g/ml per 100 nM
oligonucleotide. The mixture was vortexed and incubated for 15 min at
room temperature to allow the formation of oligonucleotide/Lipofectin
complexes. Cells were washed once with serum-free William’s E media
and then incubated with the oligonucleotide/Lipofectin mixture for 4 h.
Subsequently the oligonucleotide/Lipofectin mixture was replaced with
normal serum-containing media and incubated for the indicated times.
RNApurification frommonkeyhepatocyteswasperformedusing the
RNeasy 96 kit fromQIAGEN (Valencia, CA), as per the manufacturer’s
standard protocol. RNA was analyzed by quantitative RT-PCR for
PTP-1B expression using theTaqMan7700 system (Applied Biosystems,
FosterCity, CA). Briefly, approximately 100ng of total RNAwas analyzed
by RT-PCR using the following: forward primer, 5-GGAGTTCGAGCA-
GATCGACAA-3; reverse primer, 5-GGCCACTCTACATGG-
GAAGTC-3; and fluorescent probe, 5-AGCTGGGCGGCCATTTAC-
CAGGAT-3, all synthesized by Integrated DNATechnologies (Coralville,
IA). PTP-1B expression was then normalized to total RNA, which was
quantified using a fluorescent dye (R-11691; Molecular Probes, Eugene,
OR).The expressionof othermRNAswas also evaluatedbyusingRT-PCR
and the following primer-probes: phosphoenolpyruvate carboxykinase
(PEPCK) forward primer, 5-TGGGCTCACCTCTGTCGAA-3; reverse
primer, 5-TGCCCATCCGCGTCAT-3; probe, 5-CTGACGGAT-
TCGCCCTACGTGGTG-3; G6-P-catalytic forward primer, 5-GGTGC-
GAGCAGCCAGAAT-3; reverse primer, 5-AAAGAGCGTGCCCAG-
GTTC-3; probe, 5-CACATTGACACCACACCCTTTGCCA-3;
peroxisome proliferator-activated receptor (PPAR)- forward primer, 5-
AGCAAAGAGGTGGCCATCC-3; reverse primer, 5-CCTGCACAGC-
CTCCACG-3; probe, 5-CATCTTTCAGGGCTGCCAGTTTCGC-3;
SREBP-1c forward primer, 5-GTCCTGCGTCGAAGCTTTG-3; reverse
primer, 5-AGGTCGAACTGTGGAGGCC-3; probe, 5-AGGCCG-
AAGGCAGTGCAAGAGACTC-3.
For Western blots, monkey hepatocytes were lysed in 500 l of ex-
traction buffer [10mMTris (pH 7.4), 150mMNaCl, 2mMEDTA, 5mM
EGTA, 1%TritonX-100, 0.5%Nonidet P-40, 1mMsodiumorthovana-
date, 1 mM NaF, protease cocktail tablet (catalog no. 1697498; Roche
Molecular Biochemicals, Mannheim, Germany)]. The homogenate was
centrifuged at 14,000 g for 10 min at 4 C to pellet insoluble material.
The supernatant was saved as the final lysate and stored at80 C. Forty
micrograms of lysate were electrophoresed through a 10% Tris-glycine
gel and transferred to an Immobilon P membrane (Millipore, Billerica,
MA). The membrane was blocked in 5% milk for 30 min and then
incubated with 0.25 g/ml of either monoclonal PTP-1B antibody di-
rected against the catalytic domain (Ab-1, catalog no. PH01; Oncogene
Research Products, Cambridge,MA) or T cell phosphatase (TC-PTPase)
antibody (catalog no. PH03L) overnight. The membrane was washed
extensively and then incubated with antimouse horseradish peroxidase
secondary antibody (1:10,000; Transduction Laboratories, Lexington,
KY) for 1 h. PTP-1B protein bands were visualized using ECL-Plus re-
agents and film (Amersham, Piscataway, NJ). PTP-1B protein bands
were quantitated using ImageQuant software (Amersham).
Effects of ISIS 113715 on PTP-1B expression and glucose
tolerance in normal cynomolgus monkeys
The effects of ISIS 113715 on PTP-1B expression and glucose toler-
ancewere assessed in sevenmature normal-weight cynomolgusmonkeys
(Macaca fascicularis). Four untreated normal-weight control monkeys
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were also studied. These experiments were performed at Shin Nippon
Biomedical Laboratories USA, Ltd, (Everett, WA). Shin Nippon Bio-
medical Laboratories is accreditedby theAssociation forAssessment and
Accreditation of Laboratory Animal Care and has an Animal Welfare
Assurance issued by the Office of Laboratory Animal Welfare. The pro-
tocol complied with applicable laws and regulations concerning the hu-
mane care and use of laboratory animals and was approved by the In-
stitutional Animal Care and Use Committee (IACUC).
All monkeys underwent IVGTTs at several time points during the
study (see below). Before ASO treatment, all monkeys underwent base-
line IVGTTs. Monkeys in the treated group then received 3 mg/kg ISIS
113715, dissolved in PBS (pH 7.2), by sc injection. An IVGTT was then
performed on the fourth day after dosing. This entire cycle was repeated
with doses of 6 and 12 mg/kg over the next 2 wk, respectively. Ten days
after the 12mg/kg dose, the animals were given an additional 6 mg/kg sc
injection. After another 3 d, monkeys were anesthetized with iv pento-
barbital and phenytoin sodium so that samples of liver, skeletal muscle
(quadriceps femoris), and abdominal sc fat could be collected. Animals
were subsequently euthanized with an iv dose of pentobarbital (25 mg/
kg). The tissues were assayed for PTP-1B mRNA and protein levels as
described above.
Effects of ISIS 113715 on fasting glucose, insulin levels,
and glucose tolerance in obese, hyperinsulinemic rhesus
monkeys
To extend the results obtained in normal-weight cynomolgus mon-
keys, the effects of ISIS 113715 on fasting insulin levels and glucose
tolerancewere evaluated in 20 obese, insulin-resistant, hyperinsulinemic
rhesus monkeys (Macaca mullata). Animals were fed standard chow ad
libitum and were housed in the Assessment and Accreditation of Labo-
ratory Animal Care-accredited facilities of the California National Pri-
mate Research Center (CNPRC) in accordance with standards estab-
lished by the U.S. Animal Welfare Act and the Institute of Laboratory
Animal Resources. The experimental protocols were approved by the
IACUC at the University of California, Davis, and the CNPRC andwere
conducted in accordance with the guidelines of the National Research
Council’s Guide for the Care and Use of Laboratory Animals.
All monkeys were obese (body mass index 30 kg/m2) but normo-
glycemic; therefore, the primary end points in this part of the study were
changes in fasting insulin and lipid concentrations. During the baseline
period, blood samples were collected from overnight (16 h) fasted ani-
mals for measurements of glucose, insulin, and lipids. On a separate day
than that of the fasting blood draws, a baseline IVGTT was conducted.
After these baseline procedures, 15 monkeys underwent a dose-escala-
tion regimen, which consisted of a 2-wk period of treatment with ISIS
113715 at 1 mg/kg, followed by 6 wk at 3 mg/kg, and 3 wk at 10 mg/kg.
At the start of each dosing period, animals received ISIS 113715 sc (in the
interscapular region) on 3 alternate days during the first week (loading
dose) and once each week during each subsequent week (maintenance
dose). During the dose-escalation regimen, an IVGTTwas performed in
the second week of treatment, 48 h after the last dose.
Five additional obese, hyperinsulinemic monkeys were treated with
ISIS 113715 for 4wk at a dose of 20mg/kg, after a 1-wk baseline period.
As above, animals received ISIS 113715 on 3 alternate days during the
first week (loading dose), and once each week afterward (maintenance
dose). During the second week of treatment, fasting samples were col-
lected 48 h after dosing. An IVGTT was performed during the baseline
period and during the third week, 48 h after dosing.
Because repeated tissue biopsies were prohibited by the CNPRC,
analyses of PTP-1B gene expression and protein levels in target tissues
could not be conducted in this part of the study.
IVGTTs
IVGTTs were performed on 16 h-fasted monkeys. All procedures in
both the studies were conducted according to each institution’s IACUC
guidelines. Briefly, the monkeys were anesthetized with ketamine (10
mg/kg) and an iv catheter was inserted in each arm vein. Three baseline
samples (3 ml) were collected from one catheter at10,5, and 0 min.
Subsequently 600mg/kg of 50% dextrose were administered in the con-
tralateral catheter. Additional 3-ml blood samples were collected at 1, 3,
5, 10, 15, 20, 30, 40, and 60min in obesemonkeys and at 1, 3, 5, 10, 20,
40, and 60 min in normal-weight monkeys.
Biochemical measurements
Plasma glucose levels were measured using a glucose analyzer (Yel-
low Springs Instruments, Yellow Springs, OH). Plasma insulin levels
were measured by RIA (Linco, St. Charles, MO). Blood urea nitrogen
(BUN), bilirubin, creatinine, aspartate aminotransferase, aminotrans-
ferase, and lipid measurements were performed according to standard
methods at the CNPRC Clinical Biochemistry Laboratory.
Plasma adiponectin concentrations were measured by RIA (Linco).
Adiponectin oligomers were measured using an ELISA for human adi-
ponectin (Alpco, Salem, NH). In our laboratory, the ELISA yielded val-
ues for total adiponectin that were about 2.5 times lower than those
obtained using the RIA (21). However, the correlation between the two
methods was very high [r  0.94, 95% confidence interval (CI) 0.90–
0.96, P 0.0001]. The interassay coefficients of variation for total and
high-molecular weight (HMW) adiponectin measured by ELISA were
9.8 and 12.9%, respectively; the intraassay coefficients of variation for
total and HMW adiponectin were less than 6.9% and less than 10%,
respectively.
Data analysis
The insulin response during the IVGTT was quantified as the area
under the curve (AUC) between 0 and 60 min after dextrose infusion.
Calculations were performed by a trapezoidal method using Excel soft-
ware (Microsoft, Richmond, CA). Subsequent statistical analyses were
performed using Prizm software (version 4.03; GraphPad Software, San
Diego, CA). All variables were assessed for normality using the Kolmog-
orov-Smirnov test. Comparisons were made between control and treat-
ment groups using paired t tests or one-way ANOVA, as appropriate.
When variableswere not normally distributed, the appropriate nonpara-
metric test was used instead. For repeated measures with more than two
time points, repeated-measures ANOVAs were used, and posttests were
performed using Bonferroni’s test for multiple comparisons, with the
initial baseline measurements used as the reference. In all cases, the two-
tailed level of significance was P  0.05.
Results
Effects of ISIS 113715 in primary monkey hepatocytes
In culturedmonkeyhepatocytes, ISIS113715 treatmentdose-
dependently reduced PTP-1BmRNAexpression,with an IC50 of
less than 10 nM (Fig. 1A). Administering a control oligonucleo-
tide (141923, which contained a 6-bp mismatch to the 113715
sequence) did not significantly alter PTP-1B mRNA expression.
The specificity of the PTP-1B ASO was further investigated by
Westernblot analysis for PTP-1BandTC-PTPase, a phosphatase
that has 80% homology with PTP-1B in the enzyme’s catalytic
domain.Although ISIS 113715 reducedPTP-1Bprotein levels by
greater than 90%, no effects were observed on protein levels of
TC-PTPase after ASO treatment (Fig. 1B). The changes in TC-
PTPase mRNA expression could not be evaluated due to lack of
available genomic sequence for the monkey TC-PTPase gene.
Effects of ISIS 113715 on PTP-1B expression in normal-
weight cynomolgus monkeys
ISIS 113715 administration reduced PTP-1B mRNA expres-
sion in both liver and adipose tissue by 40–50% but did not
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affect muscle PTP-1B expression (Fig. 2A). These findings are
similar to those observed in rodent studies and are consistent
with limited distribution of these compounds to muscle (22).
Hepatic PTP-1B protein was also reduced by about 60% (Fig.
2B). PTP-1B protein levels in adipose tissue could not be deter-
mined due to the presence of an unidentified band of protein that
migrated at the same molecular weight as PTP-1B (data not
shown).
Decreased hepatic PTP-1B expression was accompanied by
marked and significant reductions in the mRNA expression of
two key gluconeogenic enzymes, PEPCK and glucose-6-phospha-
tase (Fig. 3, A and B). In abdominal sc adipose tissue, the mRNA
expression of SREBP-1c was reduced to 44 6% of control levels
(Fig. 3C), whereas PPARmRNA expression remained unchanged
(Fig. 3D).
Effects of ISIS 113715 on fasting
insulin and glucose concentrations in
normal-weight cynomolgus monkeys
Administration of ISIS 113715 to
nonobese cynomolgus monkeys dose-de-
pendently reduced fasting plasma insulin
concentrations (Fig. 4). At the 5-wk time
point, after a dose of 12 mg/kg, plasma in-
sulin concentrations in the ASO-treated an-
imalswere about 50% lower comparedwith
their baseline values (wk 5: 18.6  7.4 vs.
baseline 33.9  6.6 U/ml, P  0.05). In
contrast, fasting insulin levels tended to in-
crease in control animals over the same pe-
riod (baseline: 23.8  1.4 U/ml vs. wk 5:
40.8  7.5 U/ml, P  0.10).
The decreases in fasting insulin concen-
trations were not associated with changes in
fasting glucose concentration in either the
treated or control groups. In the control group, the glucose levels
ranged from 48 to 52 mg/dl (2.7–2.9 mmol/liter), and in the
treated group, the average values ranged from 53 to 54 mg/dl
(2.9–3.0 mmol/liter) throughout the study.
Effects of ISIS 113715 on glucose and insulin responses
during IVGTTs in normal-weight monkeys
There were no differences between the slopes of the glucose
disappearance curves, an index of glucose use, before or after
ASO treatment (data not shown). There were also no apparent
effects of ASO treatment on the glucose AUC or maximum glu-
cose concentrations observed after iv glucose administration.
However, dose-dependent reductions in the AUC for in-
sulin were observed in the treated animals. In the animals
treated with the highest dose, the 60-min AUCwas reduced by
about25%inISIS113715-treatedanimals(base-
line: 12448  8047 U  min  ml vs. wk 5:
9638  6431 U  min  ml, P  0.05). No
changes in the insulin AUCwere observed in the
control animals (baseline: 10591  1892
U  min  ml vs. wk 5: 9992  167
U  min  ml, P 0.05).
An index of insulin sensitivity can be de-
rived from the ratio of the slope of the glu-
cose disappearance curve (from 5 to 20
min) and the AUC of insulin. At wk 5, there
was a modest increase in insulin sensitivity
in the ISIS 113715-treated group compared
with baseline values (week 5: 2.12  0.47
vs. baseline: 1.61  0.89, P  0.04). How-
ever, in animals receiving saline, this index
of insulin sensitivity was unchanged at wk
5 compared with baseline values (wk 5:
1.60  0.42 vs. baseline: 1.63  0.57, P 
0.05).
Over the course of the study, no signs of
illness, malaise, or other evidence of toxicity
were observed. Therewere also no changes in
FIG. 1. Treatment of primary cynomolgus hepatocytes with a PTP-1B antisense oligonucleotide, ISIS
113715, reduces PTP-1B mRNA and protein expression. A, Primary cynomolgus monkey hepatocytes were
treated with either PTP-1B-ASO (ISIS 113715) or a 6-base mismatch control ASO (141923) at the indicated
concentrations for 24 h. PTP-1B mRNA expression was analyzed by quantitative RT-PCR (TaqMan 7700) as
described in Materials and Methods. PTP-1B mRNA expression was normalized to total RNA levels and is
expressed as percent of the levels in untreated cells. Data are expressed as means  SEM, n  4. *, P 
0.001 vs. the mismatch control ASO. Data are representative of three independent experiments. B, Primary
cynomolgus monkey hepatocytes were treated with ISIS 113715 at a concentration of 150 nM for 72 h.
PTP-1B protein expression was assessed by Western blots as described in Materials and Methods. Identical
blots were probed for TC-PTPase expression to confirm specificity of PTP-1B reduction.
FIG. 2. Effects of ISIS 113715 on PTP-1B expression in normal cynomolgus monkey tissues. Animals were
treated for 4 wk with ISIS 113715, after which tissues were harvested and evaluated for changes in PTP-
1B mRNA expression (A) or protein expression (B) as described in Materials and Methods. Scans of
representative gels are shown for reference. Protein expression in adipose tissue could not be determined
due to the presence of an interfering band on the gels (data not shown). Membranes were routinely stripped
and reprobed with a glyceraldehyde 3-phosphate dehydrogenase (G3PDH) antibody for normalization. Data
are expressed as mean SEM and have been expressed as percent saline control (control being 100%) (n 4
for the saline control and n 7 for the ISIS 113715-treated group). *, P 0.05.
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serum biochemistry parameters that were attributable to ASO
treatment (data not shown).
Effects of ISIS 113715 on fasting insulin and glucose and
responses to IVGTTs in obese, insulin-resistant rhesus
monkeys
To extend the findings observed in normal-weight cynomol-
gus monkeys, the effects of ISIS 113715 treatment on fasting
insulin and glucose levels and after iv glucose administration
were investigated in obese, insulin-resistant, hyperinsulinemic
rhesus monkeys. These monkeys spontaneously develop obesity
accompanied by insulin resistance, which over time can progress
to overt type 2 diabetes (23).
In monkeys on the low-dose/dose-escalation regimen, no sig-
nificant effects on fasting insulin concentrations were observed
over the course of the study (P 0.32, ANOVA; Fig. 5A). How-
ever, in the animals receiving the higher dose of ISIS 113715 (20
mg/kg), fasting insulin concentrationswere significantly reduced
at the end of the dosing regimen (P 0.040, ANOVA; Fig. 5A).
The reductions in fasting insulin in this groupwere accompanied
by modest but significant (P 0.019) reductions of fasting glu-
cose concentrations (Fig. 5B). In both groups, fasting glucose
concentrations remained in the normal range throughout the
study and were comparable with those observed in other studies
of rhesus monkeys (24). Consistent with the
above results, a significant reduction in in-
sulin excursions during the IVGTT was ob-
served in the animals receiving the 20mg/kg
dose but not in those on low-dose/dose-es-
calation regimen (Fig. 6). The mean insulin
AUC decreased by nearly 40%, from
14,953 2,361 U  min  ml at baseline to
9,211 2,179U  min  ml after treatment
(P  0.0008). Plasma glucose excursions
during the IVGTT were unaffected.
Other effects of PTP-1B inhibition with
ISIS 113715
We observed a small but significant re-
duction of body weight in monkeys treated
with the 20 mg/kg dose of ISIS 113715 (Ta-
ble 1). On average, monkeys lost 0.6 kg
(95% CI 0.2–1.1 kg). In contrast, monkeys
on the dose-escalation regimen gained a
small amount of weight (0.9 kg, 95% CI
0.4–1.4 kg). The decrease of body weight
was accompanied by a decrease of fasting
leptin concentrations in the high-dose group
(Table 1). Treatmentwith ISIS 113715 at 20
mg/kg was also associated with reductions
of total and low-density lipoprotein choles-
terol, of 12 and 16%, respectively (both P
0.05). In the low-dose/dose-escalation
group, the only significant biochemical
change observed in response to treatment
was a slight but significant fall in bilirubin
concentrations, which remained in the nor-
mal range. Renal and liver function, as assessed by BUN/creat-
inine and hepatic transaminase levels, respectively, were un-
changed. No significant signs of illness, including injection site
reactions, were observed.
Effects of PTP-1B inhibition on total and HMW
adiponectin concentrations
Plasma adiponectin concentrations were increased by 70 
22% in themonkeys receiving the 20mg/kg dose of ISIS 113715
for 3 wk (mean 9.6  2.6 vs. 16.1  4.1 g/ml, P  0.045). In
contrast, adiponectin was unchanged in the animals in the low-
dose/dose escalation group (mean 11.2  1.0 vs. 10.4  0.9
g/ml, P  0.27) (Fig. 7A). Measurement of adiponectin mul-
timers in the high-dose group revealed that most (75%) of the
increase in total adiponectin was due to an increase in HMW
oligomers (Fig. 7B). A concomitant increase in the proportion of
adiponectin in theHMWform [SA (25)] was also observed in the
high-dose group (baseline: 0.42  0.11 vs. after treatment:
0.60 0.07, P 0.038). With the exception of one monkey on
the dose-escalation regimen inwhich the insulin AUCduring the
IVGTTwas increasedwith treatment, the changesof adiponectin
concentrations after ISIS 113715 were proportional to the
changes of insulin AUC in all monkeys (Spearman correlation,
r  0.47, P  0.042, Fig. 7C).
FIG. 3. Significant changes in mRNA expression of hepatic gluconeogenic enzymes and adipocyte
transcription factors in ISIS 113715-treated monkeys. Animals were treated for 4 wk with ISIS 113715,
after which tissues were harvested and evaluated for changes in PEPCK (A), glucose-6-phosphatase mRNA
expression (B), SREBP1c (C), and PPAR (D) by using RT-PCR, as described in Materials and Methods. Data
are shown as mean  SEM and are expressed as percent saline control (control being 100%) (n  4 for the
saline control and n  7 for the ISIS 113715-treated group). *, P  0.05.
1674 Swarbrick et al. PTP-1B Inhibition in Monkeys Endocrinology, April 2009, 150(4):1670–1679
 at Univ of California-Davis Carlson Health Science Library on May 7, 2009 endo.endojournals.orgDownloaded from 
Discussion
In this study we investigated the metabolic effects of inhibiting
PTP-1B expression in the tissues of nonhuman primates using an
antisense oligonucleotide (ISIS 113715). Previous studies of
PTP-1B inhibition with ISIS 113715 in obese hyperinsulinemic
rodents found that PTP-1BASO treatment improves insulin sen-
sitivity, normalizes plasma glucose levels, and reduces adiposity
by down-regulating genes involved in lipogenesis in both liver
and adipose tissue (10, 12). To date, however, similar studies
have not been performed in nonhuman primates.
In the current study, we first established that PTP-1B ASO
treatment reduces PTP-1BmRNA and protein expression in cul-
tured monkey hepatocytes. Next, we demonstrated that treat-
ment of monkeys with sc administered ISIS 113715 reduces
PTP-1B mRNA in liver and adipose tissue but not skeletal mus-
cle. This is consistent with previous studies showing that ASOs
accumulate in many tissues but are poorly distributed to muscle
(26). We also demonstrated that in addition to the inhibition of
hepatic PTP-1B expression, the expression of two key gluconeo-
genic enzymes (PEPCK and glucose-6-phosphatase) is also re-
duced in the livers of ASO-treated monkeys. Finally, we showed
that in obese, insulin-resistant, hyperinsulinemic monkeys,
administration of 20 mg/kg ISIS 113715 reduced fasting con-
centrations of glucose and insulin as well as insulin excursions
during an IVGTT. Concentrations of adiponectin, an insulin-
sensitizing hormone produced by adipocytes, were also in-
creased after 20 mg/kg ISIS 113715 treatment.
This study is thus the first to report the metabolic effects of
PTP-1B inhibition in nonhumanprimates. In addition to the high
relevance of the model for human metabolic disease, an addi-
tional strength of the present study is that the effects of ASO
administration on PTP-1B mRNA and protein expression in in-
sulin-sensitive tissues were measured. Its main limitations were
that food intake and changes in body composition were not as-
sessed and that we did not have a formal control group for the
studies of obese, insulin-resistant monkeys treated with ISIS
113715. However, the lack of effects on indices of insulin sen-
sitivity or plasma adiponectin concentrations in the monkeys
receiving lower doses of ISIS 113715 (on the dose-escalation
regimen) strongly suggests that the observed effects are not a
result of the treatment regimen per se but are due to the effects
of the higher dose to inhibit PTP-1B.
Most of the metabolic effects of PTP-1B ASO treatment ob-
served in the study (i.e. reduced fasting insulin and glucose con-
centrations and an attenuated insulin response to an IVGTT) are
likely due to ASO-mediated inhibition of PTP-1B expression in
the livers of treated animals. In this regard, our results are con-
sistent with those ofHaj et al. (27), who reported that in high-fat
diet-fed mice, the effects of overall PTP-1B deficiency were
largely reversed by adenovirally mediated overexpression of
PTP-1B in the liver. The importance of normal hepatic insulin
signaling for the maintenance of glucose homeostasis in mice is
well illustrated by the phenotype of liver-specific insulin receptor
knockoutmice, which exhibit dramatic insulin resistance, severe
glucose intolerance, and an inability of insulin to suppress he-
patic glucoseproduction (28).However,wecannot excludePTP-
1B-mediated effects in extrahepatic tissues, particularly adipose
FIG. 5. Changes of fasting insulin and glucose concentrations in obese, insulin-
resistant monkeys treated with ISIS 113715. A, Fasting insulin concentrations. B,
Fasting glucose concentrations. Data are shown as mean  SEM. *, P  0.05 (n 
15 for the low dose/dose escalation group and n  5 for the high dose group).
FIG. 4. Dose-response effects of ISIS 113715 on 16 h-fasted insulin levels in
normal monkeys. The mean concentrations of insulin at baseline (0 mg/kg), 3, 6,
and 12 mg/kg are shown as gray squares (n  7). For reference, the control
values at the start of study (depicted at 0 mg/kg) and at the end of treatment
(depicted at 12 mg/kg) are shown as black triangles (n  4). Data are shown as
mean  SEM.
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tissue and the hypothalamus (see below). Interestingly, the ef-
fects of PTP-1B inhibition vary among different cell types in the
liver: we have demonstrated elsewhere that a 50% reduction in
PTP-1Bexpression inwhole-liver extracts corresponds toamuch
greater reduction of PTP-1B expression in hepatocytes (29) than
in nonparenchymal cells, although basal PTP-1B expression is
much (6- to 8-fold) higher in the latter (30).
Inhibition of PTP-1B in adipose tissue may also have con-
tributed to the improved insulin sensitivity because high-dose
ISIS 113715 treatment substantially increased (by 70%) circu-
lating concentrations of adiponectin, an insulin-sensitizing hor-
mone produced exclusively by adipocytes (15). A relationship
between PTP inhibition and increased adiponectin levels has
been suggested previously: treatment of ZDF rats with a non-
specific PTP inhibitor, bis(maltolato) oxovanadium (iv), re-
stored plasma adiponectin concentrations to levels seen in nor-
mal rats (31). In the present study, significantly increased plasma
adiponectin concentrations were observed only in monkeys
treated with the higher dose of ISIS 113715, and the changes of
adiponectin concentrations in both the low- and high-dosemon-
keys were proportional to the reduction of insulin responses,
measured by the insulin AUC during an IVGTT. The increase of
adiponectin concentrations in the high-dose-treated monkeys
was largely due to a greater amount of the HMW oligomer,
changes which are preferentially associated with improved he-
patic insulin sensitivity (25). Increased con-
centrations of HMW oligomers are com-
monly observed after weight loss associated
with gastric bypass surgery (32) and treat-
ment with thiazolidinediones (25).Moreover,
replacementofdifferentadiponectinmultimers
in adiponectin-deficient mice demonstrates
that the HMW form most effectively lowers
glucose concentrations (25).
The increase of adiponectin concentra-
tions observed in response to high-dose
PTP-1BASO treatmentmayhave been due to
direct effects of PTP-1B silencing in adipo-
cytes (resulting in improved insulin sensitiv-
ity) or secondary effects from improved he-
patic insulin signaling. Evidence to support a
primary effect on adipose tissue includes the
reported ability of PTP-1B ASO treatment to
reduce adipocyte mass in ob/ob mice via in-
hibition of lipogenic gene expression (12).
Consistent with these findings, in the present
study, we found that PTP-1B ASO treatment
was associated with reduced mRNA expres-
sion of SREBP-1c, a transcription factor that
regulates lipogenesis in adipocytes. Smaller
adipocytes are generallymore sensitive to the
antilipolytic effects of insulin and as a result
secrete less free fatty acids (33). Relative to
larger, insulin-resistant adipocytes, smaller
adipocytes also secrete lower amounts of
proinflammatory cytokines (34) and more
adiponectin (35, 36). Whereas we did not di-
rectly assess fatmassoradipocyte size in thepresent study,wedid
observe a small but significant reduction of body weight in the
monkeys treated with the high dose (20 mg/kg). This was ac-
companied by a significant decrease of plasma leptin, which is
consistent with a reduced adipose mass and cell size. Unlike lep-
tin, adiponectin concentrations usually increase afterweight loss
(17). It is unlikely thatweight loss was themost important factor
responsible for the observed increase of adiponectin concentra-
tions in the study, however, because the degree of weight loss in
these monkeys (0.6 kg or 4% of body weight) is at the lower
limit of that associated with significant increases of adiponectin
concentrations in humans (37, 38).
It remains to be demonstrated whether blocking PTP-1B in
adipose tissue directly improves overall insulin sensitivity.
PTP-1B knockout mice do not exhibit differences in insulin sig-
naling or glucose uptake in adipose tissue relative to wild-type
mice (5). In fact, investigation of glucose uptake in isolated adi-
pocytes from PTP-1B-deficient mice indicates that the response
to insulin is significantly attenuated relative to wild-type mice
(14). Similarly, PTP-1B ASO treatment does not seem to affect
insulin signaling in adipose tissue of ob/obmice (12), although it
was shown to reduce PPARmRNAexpression in addition to its
inhibitory effects on SREBP-1. In the leanmonkeys, we observed
a significant decrease in SREBP-1c expression, whereas expres-
sion of PPAR remained unchanged. The differences in PPAR
FIG. 6. Inhibition of PTP-1B with ISIS 113715 improves insulin sensitivity in obese, insulin-resistant rhesus
monkeys. A, IVGTT results (insulin and glucose responses) from monkeys on the low-dose/dose-escalation
regimen. B, IVGTT results (insulin and glucose responses) from monkeys on the high-dose regimen. Data
are shown as mean  SEM (n  15 for the low dose/dose escalation group and n  5 for the high dose
group).
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expression between the studies conducted in obese mice and the
present study may be explained, at least in part, by the very
different models used (leptin-deficient ob/obmice vs. lean mon-
keys). However, it is more important to note that the increase in
adiponectin levels in nonhuman primates treated with the
PTP-1B ASO was not accompanied by an increase in PPAR
expression.BothSREBP-1candPPARarepositive regulators of
adiponectin gene transcription (40, 41), and mice with an adi-
pose-specific knockout of PPAR have reduced circulating adi-
ponectin concentrations (42). Therefore, it is likely that other
factors, perhaps related to insulin sensitivity in adipose tissue
and/or liver, adipocyte size or lipid content, contribute to the
increased adiponectin secretion. Other influences may include
autonomic nervous system-mediated cross talk between the liver
and visceral adipose tissue (43) because visceral adipose tissue is a
major determinant of plasma adiponectin concentrations (44) or
perhaps an as-yet-unidentified humoral factor. These possibilities
should be addressed in future studies.
Lastly, although ASOs generally are not targeted to the brain
(45), it is also possible that the observed effects of PTP-1B ASO
treatment in the present study were due to PTP-1B inhibition in
insulin receptor-containing areas of the hypothalamus, which
regulate energy balance and are accessible to the systemic blood
supply, such as the median eminence (46). Notably, neuronal-
specific deletion of PTP-1B in mice is associated with higher adi-
ponectin levels in addition to improved glucose homeostasis (47).
The substantial reduction of fasting insulin concentrations
and marked improvement of insulin sensitivity observed in the
obese, insulin-resistant, hyperinsulinemic monkeys in the cur-
rent study supports the therapeutic potential for ISIS 113715 in
the treatment of insulin resistance and type 2 diabetes. Further-
more, the magnitude of the decrease of fasting insulin concen-
trations (40%) observed in the obesemonkeys treatedwith the
PTP-1B ASO is comparable with that observed after thiazo-
lidinedione (pioglitazone) treatment (39). While the manuscript
was in preparation, the effects of ISIS 113715 were evaluated in
healthy volunteers who received four doses of ISIS 113715 or a
placebo (PBS) by parenteral administration in a randomized,
double-blind, dose-escalation phase I trial. The efficacy of the
two highest doses of ISIS 113715 (5.0 and 7.5 mg/kg) was as-
sessed with an IVGTT. All ISIS 113715-treated volunteers (n
6) exhibited increased insulin sensitivity comparedwithplacebo-
treated subjects (n  2), which was reflected as a decrease in
insulin AUC during an IVGTT (30). ISIS 113715 was generally
well tolerated and no subjects experienced hypoglycemia, even
after a 16-h fast. A pilot study was also conducted in which the
effects of ISIS 113715 were studied in drug naïve subjects with
type 2 diabetes. In that study, ISIS 113715 caused a reduction in
both fed and fasted glucose levels aswell as total and low-density
lipoprotein cholesterol concentrations, which is consistent with
the primate data in the present study (30). The dose that pro-
duced significant effects in drug-naïve human diabetic subjects
was 200 mg/wk (2 mg/kg, as opposed to 20 mg/kg in the cur-
rent monkey study). To date, the drug has been evaluated up to
doses of 600mg/wk, and there have been no clinically significant
effects on any organ system. ISIS 113715 has beenwell tolerated
in clinical studies to date.
In summary, ISIS 113715 treatment reduces PTP-1B expres-
sion in insulin-sensitive tissues in monkeys, resulting in signifi-
cant improvements of insulin sensitivity and reductions in fasting
insulin concentrations in both normal-weight andobese, insulin-
resistant monkeys. Concentrations of adiponectin, an insulin-
sensitizing adipocyte-derived hormone, are low in obese mon-
keys and increase with ISIS 113715 treatment in proportion to
the improvements of insulin sensitivity. Therefore, using PTP-1B
antisense drugs to overcome defects in insulin signaling may be
a promising approach for the treatment and prevention of obe-
TABLE 1. Changes of body weight, lipids, and other biochemical measurements in obese, insulin-resistant rhesus monkeys
treated with ISIS 113715
Low dose (n  15) High dose (n  5)
Parameter End of baseline After 10 mg/kg P End of baseline After 20 mg/kg P
Adiposity
Body weight (kg) 15.3  0.4 16.2  0.5 0.016 14.4  2.4 13.8  2.3 0.002
Leptin (ng/ml) 12.6  2.4 12.7  3.0 0.45a 8.2  1.0 4.9  0.6 0.047
Lipids
Total cholesterol (mmol/liter) 4.12  0.36 3.75  0.49 0.24 4.50  0.28 3.95  0.27 0.029
HDL cholesterol (mmol/liter) 1.37  0.16 1.42  0.17 0.67 1.67  0.16 1.72  0.15 0.15
LDL cholesterol (mmol/liter) 2.02  0.22 1.75  0.26 0.36 2.18  0.26 1.82  0.17 0.043
Triglycerides (mmol/liter) 1.54  0.58 1.21  0.42 0.10a 1.42  0.37 0.90  0.13 0.16
Cholesterol to HDL ratio 3.9  1.0 2.9  0.3 0.083a 2.8  0.3 2.3  0.1 0.089
Other biochemical data
Creatinine (mol/liter) 67  3 66  3 0.68a 66  5 66  6 0.99
ALT (U/liter) 49  5 46  3 0.45 63  26 49  17 0.19
AST (U/liter) 25  1 36  5 0.11 29  3 27  2 0.49
BUN (mmol/liter) 6.4  0.3 6.0  0.3 0.12 6.5  0.4 6.0  0.6 0.13
Total bilirubin (mol/liter) 3.8  0.5 2.5  0.2 0.016a 3.4  0.5 3.4  1.3 0.99
Data are shown as mean  SEM. Significant P values (P  0.05) are highlighted in bold. HDL, High-density lipoprotein; LDL, low-density lipoprotein; ALT, alanine
transaminase; AST, aspartate aminotransferase.
a Nonparametric Wilcoxon signed rank test.
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sity-associated insulin resistance and type2diabetes, devastating
diseases that are rapidly increasing in prevalence worldwide.
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